Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Travere Therapeutics Inc. Common Stock trades at $54.58 (market cap $5.02B), while Direxion Daily FTSE China Bull 3x Shares trades at $24.76 (market cap $601.74M). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 8.3× Direxion Daily FTSE China Bull 3x Shares's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Direxion Daily FTSE China Bull 3x Shares for 26 Days on average.
| TVTX | YINN | |
|---|---|---|
Market Cap | $5.02B | $601.74M |
Volume | 2,060,842 | 1,449,514 |
Sector | Health | Leveraged / Inverse |
52-Week High | $67.52 | $52.69 |
52-Week Low | $26.79 | $21.45 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $5.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
YINN trades at $25.06, up 0.36% on the day, with technical indicators signaling a bearish trend from moving averages and neutral oscillators. Key financial ratios such as P/E, P/S, and ROE are unavailable in the provided data. A dividend of $0.56 is scheduled for payment on September 29, 2026. Recent news highlights China's economic policies and energy sector dynamics, which may indirectly influence the stock's performance.
The outlook for YINN is cautious due to bearish technical signals and lack of fundamental data. Risks include reliance on macroeconomic factors in China and potential regulatory changes. Investment opportunities hinge on future financial disclosures and positive developments in related sectors, but current indicators suggest limited upside without stronger earnings or valuation support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
